trial

Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia

NCTId NCT00169065
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 38 (actual)
Sponsored by Harvard Medical School (HMS and HSDM)
Primary completion 2002-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
38 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
1998-08
Primary completion
2002-06
Eligibility
ALL · 20 Years · 60 Years

Interventions & indications

Drugs
ClozapineOlanzapine

Sponsors

Harvard Medical School (HMS and HSDM)Lead Sponsor
National Institute of Mental Health (NIMH)Collaborator
Dartmouth-Hitchcock Medical CenterCollaborator
Commonwealth Research Center, MassachusettsCollaborator
Eli Lilly and CompanyCollaborator

Investigators

1
Alan I. Green, MDPrincipal Investigator

Sites

1 total
Jamaica Plain, United States

Facts & assertions

4 sourced
Enrollment
38
Phase
PHASE4
Primary Completion Date
2002-06
Status
COMPLETED
relationships
The graph out of here
drug
Clozapine
drug
Olanzapine
drug
lead_sponsor
Harvard Medical School (HMS and HSDM)
company
collaborator
National Institute of Mental Health (NIMH)
company
Dartmouth-Hitchcock Medical Center
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Alan I. Green, MD
person